Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Eur J Pharm Biopharm ; 154: 116-126, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32580049

ABSTRACT

Simulated human intestinal media, have proved to be a useful biopharmaceutics tool as a dissolution media for predicting in vivo dissolution and pharmacokinetic profile in humans. During drug product development preclinical animal models are also required to assess drug product performance, and there is a need to develop species specific intestinal media to similarly predict in vivo pharmacokinetic profiles in each preclinical model. Pigs, are increasingly being used in preclinical drug development, however to date there is a lack of quantitative information about the composition of porcine gastrointestinal (GI) fluids. As a result, a porcine biorelevant medium has not yet been developed, which is essential to improve interpretation and forecast of preclinical results using biorelevant in vitro dissolution studies. GI fluid samples, were collected from landrace pigs, and characterized. Fasted State Simulated Intestinal Fluid of pigs (FaSSIFp) was developed based on the physiological composition of the GI fluids in terms of pH, buffer capacity, osmolality, surface tension, as well as the bile salt, phospholipid and free fatty acid content. This study demonstrated that FaSSIFp was superior at predicting the solubility of the six model drugs in porcine intestinal fluids (PIF). A markedly high correlation (r2 0.98) was observed between the solubility obtained in PIF and FaSSIFp, whereas poor correlation (r2 0.12) was found for the solubility of the model drugs between human FaSSIF and PIF. This confirms that species specific biorelevant intestinal media are crucial to provide more accurate predictions of pharmacokinetic studies in preclinical models. Additionally, the availability of a species specific intestinal medium offers the potential to improve in vitro-in silico approaches to predict in vivo absorption and to reduce the overall number of animals needed in oral drug product development testing.


Subject(s)
Bile Acids and Salts/chemistry , Biological Products/chemistry , Drug Development/methods , Gastric Acid/chemistry , Gastric Mucosa/chemistry , Intestine, Small/chemistry , Animals , Bile Acids and Salts/metabolism , Biological Products/metabolism , Body Fluids/chemistry , Body Fluids/drug effects , Body Fluids/metabolism , Celecoxib/pharmacokinetics , Drug Evaluation, Preclinical/methods , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Humans , Hydrogen-Ion Concentration , Intestinal Absorption/drug effects , Intestinal Absorption/physiology , Intestine, Small/drug effects , Intestine, Small/metabolism , Ketoconazole/pharmacokinetics , Osmolar Concentration , Swine
SELECTION OF CITATIONS
SEARCH DETAIL